In a clinical trial on the effects of LY2405319 (an FGF21 variant) in obese patients with T2DM, it has been demonstrated that this compound significantly improved body weight, fasting insulin, and adiponectin; decreased LDL and triglycerides; and increased HDL [112]. This evidence concerns the gene ADIPOQ and type 2 diabetes mellitus.